|
|
|
|
| LEADER |
00000cam a2200000 i 4500 |
| 001 |
EBSCO_on1085177936 |
| 003 |
OCoLC |
| 005 |
20231017213018.0 |
| 006 |
m o d |
| 007 |
cr cnu---unuuu |
| 008 |
190209s2019 onc ob 001 0 eng d |
| 040 |
|
|
|a EBLCP
|b eng
|e rda
|e pn
|c EBLCP
|d N$T
|d OCLCF
|d YDX
|d OCLCQ
|d OCLCO
|d OCLCQ
|d OCLCO
|
| 019 |
|
|
|a 1084504890
|a 1084678755
|
| 020 |
|
|
|a 1773617990
|
| 020 |
|
|
|a 9781773617992
|q (electronic bk.)
|
| 035 |
|
|
|a (OCoLC)1085177936
|z (OCoLC)1084504890
|z (OCoLC)1084678755
|
| 050 |
|
4 |
|a R853.B54
|
| 072 |
|
7 |
|a HEA
|x 012000
|2 bisacsh
|
| 072 |
|
7 |
|a HEA
|x 020000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 004000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 101000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 109000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 029000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 040000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 092000
|2 bisacsh
|
| 082 |
0 |
4 |
|a 610.28
|2 23
|
| 049 |
|
|
|a UAMI
|
| 100 |
1 |
|
|a Selmy, Mohamed A.,
|e author.
|
| 245 |
1 |
0 |
|a Proteomics in Biomarker Identification /
|c Mohamed A. Selmy.
|
| 250 |
|
|
|a E-book edition.
|
| 264 |
|
1 |
|a Oakville, ON, Canada :
|b Society Publishing,
|c 2019.
|
| 300 |
|
|
|a 1 online resource
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 588 |
|
|
|a Online resource; title from PDF title page (EBSCO, viewed June 18, 2019).
|
| 504 |
|
|
|a Includes bibliographical references and index.
|
| 505 |
0 |
|
|a Cover; Half Title Page; Title Page; Copyright Page; About The Author; Table of Contents; List of Figures; List of Tables; List of Abbreviations; Preface; Chapter 1 Biomarkers: An Overview; 1.1. Introduction; 1.2. Classification of Biomarkers; 1.3. Types of Biomarkers Based on Different "Omics; 1.4. Biomarker Specifications; 1.5. An Overview of Biomarkers In A Clinical Scenario; 1.6. Characters of Ideal Biomarkers; 1.7. Biomarkers or Clinical Endpoints; 1.8. Merits And Demerits of Biomarkers As Surrogate Endpoints; 1.9. Which Are The Biomarkers Used?; 1.10. Gist of Significance of Biomarkers
|
| 505 |
8 |
|
|a 1.11. Case Studies of Analysis of Biomarkers In A Clinical Context1.12. Discovery and Validation of Biomarkers; 1.13. Biomarkers In A Clinical Scenario: Approach; 1.14. Valid Biomarkers and Clinical Research; 1.15. Case Study of Biomarkers Detected By Metabolomics; 1.16. Summary; References; Chapter 2 Proteomics: An Overview of Techniques Involved; 2.1. Design of Biomarkers; 2.2. Biobanking of Samples; 2.3. Proteomics And Discovery of Biomarkers; 2.4. A Quick Snapshot; 2.5. Techniques For Biomarker Discovery Using Proteomics; 2.6. The Mass Analyzers; 2.7. Variations of Ms
|
| 505 |
8 |
|
|a 2.8. Variations In Ms Technologies In Proteomics2.9. Ief Fractionation Methods; 2.10. 2D Gel Electrophoresis (2-De); 2.11. 2D Difference Gel Electrophoresis (2D-Dige); 2.12. Stable Isotope Labeling by Amino Acids In Cell Culture (SILAC); 2.13. Isotope-Coded Affinity Tag (ICAT); 2.14. Western Blotting; 2.15. 18O Stable Isotope Labeling; 2.16. Isobaric Tagging Reagent For Absolute Quantitation (ITRAQ); 2.17. Ce-Ms; 2.18. Stable Isotope Dilution Mass Spectrometry (SID-MS); 2.19. Microarrays; 2.20. Multidimensional Protein Identification Technology (MUDPIT); 2.21. Label-Free Techniques
|
| 505 |
8 |
|
|a 2.22. Another Proteomics For Biomarker Discovery2.23. Bioinformatics and Proteomics And Biomarkers; 2.24. Glimpses of Discovery of Biomarkers Using Proteomics; 2.25. Case Studies: Biomarkers of Bladder Cancer Using Proteomics; 2.26. Final Note; References; Chapter 3 Microbial Biomarkers Proteomics; 3.1. Typing Of Microbes; 3.2. Typing Methods; 3.3. Phenotypic Methods; 3.4. Genotypic Methods; 3.5. Diagnosis Of Microbial Infections Using Biomarkers; 3.6. What Is The Role Of A Biomarker From The Host?; 3.7. Biomarkers And Antibiotics: A Scenario; 3.8. Biomarkers That Are Routinely Analyzed
|
| 505 |
8 |
|
|a 3.9. Biomarkers For The Future3.10. What's New?; 3.11. Proteome For Biomarkers Of Bacteria And Virus; 3.12. Host-Pathogen Protein-Protein Interactions; 3.13. Intact Proteins; 3.14. Direct Interactions And Their Detections; 3.15. Posttranslational Modifications That Are Regulated By Pathogen; 3.16. Summary; References; Chapter 4 Plant Biomarkers Discovery by Proteomics; 4.1. Introduction; 4.2. Why Proteomics For Plant Biomarkers?; 4.3. Approaches For Plant Biomarkers; 4.4. Proteomics For Reactive Oxygen Species Research; 4.5. Stress Responses In Two Plants: Proteomics For Biomarkers
|
| 500 |
|
|
|a 4.6. Proteomics For Plants Infected With Virus: Biomarkers
|
| 590 |
|
|
|a eBooks on EBSCOhost
|b EBSCO eBook Subscription Academic Collection - Worldwide
|
| 650 |
|
0 |
|a Biochemical markers.
|
| 650 |
|
0 |
|a Proteomics.
|
| 650 |
|
2 |
|a Biomarkers
|
| 650 |
|
2 |
|a Proteomics
|
| 650 |
|
6 |
|a Marqueurs biologiques.
|
| 650 |
|
6 |
|a Protéomique.
|
| 650 |
|
7 |
|a HEALTH & FITNESS
|x Holism.
|2 bisacsh
|
| 650 |
|
7 |
|a HEALTH & FITNESS
|x Reference.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Alternative Medicine.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Atlases.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Essays.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Family & General Practice.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Holistic Medicine.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Osteopathy.
|2 bisacsh
|
| 650 |
|
7 |
|a Biochemical markers
|2 fast
|
| 650 |
|
7 |
|a Proteomics
|2 fast
|
| 776 |
0 |
8 |
|i Print version:
|a Selmy, Mohamed A.
|t Proteomics in Biomarker Identification.
|d Ashland : Delve Publishing, ©2019
|
| 856 |
4 |
0 |
|u https://ebsco.uam.elogim.com/login.aspx?direct=true&scope=site&db=nlebk&AN=2014045
|z Texto completo
|
| 938 |
|
|
|a ProQuest Ebook Central
|b EBLB
|n EBL5655653
|
| 938 |
|
|
|a EBSCOhost
|b EBSC
|n 2014045
|
| 938 |
|
|
|a YBP Library Services
|b YANK
|n 16023425
|
| 994 |
|
|
|a 92
|b IZTAP
|
